Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 8 | 2012 | 126 | 2.210 |
Why?
|
| Receptor, Parathyroid Hormone, Type 1 | 9 | 2009 | 11 | 2.050 |
Why?
|
| Parathyroid Hormone | 7 | 2009 | 44 | 1.720 |
Why?
|
| Breast Neoplasms | 9 | 2012 | 1213 | 1.340 |
Why?
|
| Wounds, Nonpenetrating | 8 | 2020 | 118 | 1.140 |
Why?
|
| Disease Models, Animal | 6 | 2012 | 2238 | 0.820 |
Why?
|
| Textiles | 1 | 2020 | 10 | 0.650 |
Why?
|
| Masks | 1 | 2020 | 23 | 0.650 |
Why?
|
| Exposure to Violence | 1 | 2019 | 5 | 0.620 |
Why?
|
| Intimate Partner Violence | 1 | 2019 | 26 | 0.600 |
Why?
|
| Receptors, Parathyroid Hormone | 3 | 2008 | 4 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 183 | 0.560 |
Why?
|
| Peptide Fragments | 5 | 2009 | 417 | 0.550 |
Why?
|
| Iodine | 1 | 2017 | 20 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 210 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.510 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 67 | 0.510 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 251 | 0.500 |
Why?
|
| Pandemics | 1 | 2020 | 676 | 0.450 |
Why?
|
| Contrast Media | 1 | 2017 | 429 | 0.440 |
Why?
|
| Bone and Bones | 3 | 2012 | 145 | 0.410 |
Why?
|
| COS Cells | 6 | 2009 | 174 | 0.390 |
Why?
|
| Disulfides | 2 | 2009 | 66 | 0.350 |
Why?
|
| Recombinant Proteins | 4 | 2007 | 704 | 0.340 |
Why?
|
| Benzophenones | 2 | 2008 | 19 | 0.340 |
Why?
|
| Mice, SCID | 5 | 2012 | 517 | 0.340 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 63 | 0.340 |
Why?
|
| Animals | 17 | 2012 | 20962 | 0.330 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 45 | 0.330 |
Why?
|
| Drug Discovery | 1 | 2011 | 98 | 0.320 |
Why?
|
| Protein Structure, Tertiary | 7 | 2008 | 674 | 0.310 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2009 | 9 | 0.310 |
Why?
|
| rho-Associated Kinases | 1 | 2009 | 18 | 0.310 |
Why?
|
| Cyclic AMP | 2 | 2009 | 145 | 0.310 |
Why?
|
| Tissue Engineering | 2 | 2007 | 144 | 0.300 |
Why?
|
| Cross-Linking Reagents | 2 | 2008 | 117 | 0.300 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 279 | 0.290 |
Why?
|
| Photoaffinity Labels | 1 | 2008 | 5 | 0.280 |
Why?
|
| Phenylalanine | 1 | 2008 | 26 | 0.280 |
Why?
|
| Humans | 33 | 2024 | 64279 | 0.280 |
Why?
|
| Models, Molecular | 7 | 2009 | 1159 | 0.280 |
Why?
|
| Protein Interaction Mapping | 1 | 2008 | 68 | 0.270 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 2 | 2020 | 10 | 0.250 |
Why?
|
| Ligands | 5 | 2009 | 417 | 0.250 |
Why?
|
| Photochemistry | 1 | 2006 | 24 | 0.240 |
Why?
|
| Methionine | 1 | 2006 | 57 | 0.240 |
Why?
|
| Mice | 8 | 2012 | 11003 | 0.230 |
Why?
|
| Injury Severity Score | 5 | 2020 | 116 | 0.230 |
Why?
|
| Female | 20 | 2024 | 33382 | 0.220 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 240 | 0.220 |
Why?
|
| Spleen | 2 | 2020 | 483 | 0.220 |
Why?
|
| In Vitro Techniques | 2 | 2020 | 490 | 0.210 |
Why?
|
| Mice, Inbred NOD | 3 | 2012 | 526 | 0.210 |
Why?
|
| Transfection | 5 | 2011 | 695 | 0.210 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 6 | 0.200 |
Why?
|
| Patient Transfer | 1 | 2024 | 92 | 0.200 |
Why?
|
| Cysteine | 3 | 2009 | 108 | 0.200 |
Why?
|
| Placebos | 1 | 2003 | 72 | 0.200 |
Why?
|
| Industry | 1 | 2003 | 60 | 0.200 |
Why?
|
| Ethics, Medical | 1 | 2003 | 40 | 0.200 |
Why?
|
| Signal Transduction | 2 | 2009 | 3070 | 0.190 |
Why?
|
| Osteoporosis | 1 | 2003 | 108 | 0.190 |
Why?
|
| Health Care Rationing | 1 | 2022 | 21 | 0.180 |
Why?
|
| Standard of Care | 1 | 2022 | 27 | 0.180 |
Why?
|
| Liver | 2 | 2020 | 868 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2020 | 511 | 0.180 |
Why?
|
| Protein Conformation | 5 | 2009 | 784 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2011 | 1494 | 0.170 |
Why?
|
| Retrospective Studies | 10 | 2022 | 6742 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2022 | 221 | 0.160 |
Why?
|
| Filtration | 1 | 2020 | 20 | 0.160 |
Why?
|
| Air Microbiology | 1 | 2020 | 11 | 0.160 |
Why?
|
| Permeability | 1 | 2020 | 50 | 0.160 |
Why?
|
| Aerosols | 1 | 2020 | 47 | 0.160 |
Why?
|
| Trauma Centers | 7 | 2020 | 127 | 0.160 |
Why?
|
| Traumatology | 1 | 2019 | 15 | 0.150 |
Why?
|
| New England | 6 | 2020 | 269 | 0.150 |
Why?
|
| Community-Institutional Relations | 1 | 2019 | 42 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 788 | 0.150 |
Why?
|
| Stromal Cells | 2 | 2010 | 69 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 544 | 0.150 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 1621 | 0.150 |
Why?
|
| Cell Movement | 2 | 2012 | 466 | 0.140 |
Why?
|
| Bone Marrow Cells | 2 | 2010 | 237 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 2 | 2010 | 174 | 0.140 |
Why?
|
| Particle Size | 1 | 2020 | 421 | 0.140 |
Why?
|
| Water | 1 | 2020 | 314 | 0.140 |
Why?
|
| Middle Aged | 12 | 2024 | 17923 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 210 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2009 | 614 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 297 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 37 | 0.130 |
Why?
|
| Amino Acid Sequence | 4 | 2009 | 1597 | 0.130 |
Why?
|
| Alcoholism | 1 | 2020 | 323 | 0.130 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2008 | 248 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2009 | 668 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2019 | 490 | 0.130 |
Why?
|
| Spinal Injuries | 1 | 2017 | 12 | 0.130 |
Why?
|
| Emigration and Immigration | 1 | 2017 | 26 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2019 | 381 | 0.130 |
Why?
|
| Biotechnology | 1 | 2017 | 45 | 0.130 |
Why?
|
| Public Policy | 1 | 2017 | 41 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 783 | 0.120 |
Why?
|
| Hospitals | 1 | 2019 | 390 | 0.120 |
Why?
|
| Neoplasm Transplantation | 2 | 2007 | 167 | 0.120 |
Why?
|
| Molecular Sequence Data | 3 | 2009 | 1997 | 0.120 |
Why?
|
| Nanoparticles | 2 | 2020 | 523 | 0.120 |
Why?
|
| Cervical Vertebrae | 1 | 2017 | 118 | 0.120 |
Why?
|
| Cell Membrane | 2 | 2009 | 501 | 0.120 |
Why?
|
| Aged | 9 | 2022 | 14664 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1164 | 0.110 |
Why?
|
| Male | 12 | 2024 | 30323 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2009 | 1551 | 0.090 |
Why?
|
| Protein Engineering | 2 | 2011 | 85 | 0.090 |
Why?
|
| Risk Factors | 4 | 2017 | 5342 | 0.090 |
Why?
|
| Adolescent | 4 | 2017 | 6305 | 0.090 |
Why?
|
| Bone Transplantation | 1 | 2012 | 30 | 0.090 |
Why?
|
| Arthropod Proteins | 1 | 2011 | 8 | 0.090 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 44 | 0.090 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2010 | 2 | 0.090 |
Why?
|
| Kidney | 1 | 2013 | 455 | 0.080 |
Why?
|
| Protein Structure, Secondary | 2 | 2009 | 260 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2011 | 49 | 0.080 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2008 | 113 | 0.080 |
Why?
|
| Craniocerebral Trauma | 1 | 2011 | 55 | 0.080 |
Why?
|
| Foreign-Body Migration | 1 | 2010 | 23 | 0.080 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2010 | 31 | 0.080 |
Why?
|
| United States | 2 | 2019 | 7923 | 0.080 |
Why?
|
| Cell Communication | 1 | 2010 | 132 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2010 | 101 | 0.080 |
Why?
|
| Rib Fractures | 1 | 2010 | 22 | 0.080 |
Why?
|
| Hydrocephalus | 1 | 2010 | 43 | 0.080 |
Why?
|
| Warfarin | 1 | 2011 | 122 | 0.080 |
Why?
|
| Adult | 7 | 2017 | 17133 | 0.080 |
Why?
|
| Herniorrhaphy | 1 | 2010 | 72 | 0.080 |
Why?
|
| Bone Resorption | 1 | 2009 | 45 | 0.080 |
Why?
|
| Breast | 1 | 2011 | 190 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 110 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 324 | 0.070 |
Why?
|
| Abdominal Injuries | 1 | 2009 | 34 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2009 | 105 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2011 | 233 | 0.070 |
Why?
|
| Factor Xa | 1 | 2008 | 5 | 0.070 |
Why?
|
| Bombyx | 1 | 2007 | 10 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 373 | 0.070 |
Why?
|
| Binding Sites | 2 | 2008 | 914 | 0.070 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 48 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 2218 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2008 | 140 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 62 | 0.070 |
Why?
|
| Baculoviridae | 1 | 2007 | 25 | 0.070 |
Why?
|
| Insecta | 1 | 2007 | 37 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 1669 | 0.060 |
Why?
|
| DNA Primers | 1 | 2007 | 295 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 365 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 851 | 0.060 |
Why?
|
| Sodium Chloride | 1 | 2006 | 64 | 0.060 |
Why?
|
| Bioreactors | 1 | 2005 | 36 | 0.060 |
Why?
|
| Protein Transport | 1 | 2007 | 405 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 666 | 0.060 |
Why?
|
| Phosphorylcholine | 1 | 2006 | 44 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2008 | 482 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 239 | 0.060 |
Why?
|
| Femur | 1 | 2005 | 54 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2007 | 718 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 386 | 0.060 |
Why?
|
| Base Sequence | 1 | 2007 | 1332 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2011 | 802 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2006 | 2177 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 108 | 0.050 |
Why?
|
| Cell Survival | 1 | 2005 | 582 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 927 | 0.050 |
Why?
|
| Protein Binding | 1 | 2008 | 1618 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2009 | 697 | 0.050 |
Why?
|
| Receptors, Vitronectin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Prognosis | 1 | 2007 | 1769 | 0.050 |
Why?
|
| Obesity | 1 | 2010 | 1248 | 0.050 |
Why?
|
| Trauma Severity Indices | 2 | 2013 | 34 | 0.050 |
Why?
|
| Organ Dysfunction Scores | 1 | 2022 | 23 | 0.050 |
Why?
|
| Health Priorities | 1 | 2022 | 28 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1187 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2002 | 135 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1001 | 0.040 |
Why?
|
| Cell Line | 1 | 2005 | 2055 | 0.040 |
Why?
|
| Boston | 1 | 2022 | 255 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 89 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 26 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2024 | 507 | 0.040 |
Why?
|
| Hospitalization | 2 | 2022 | 1368 | 0.040 |
Why?
|
| Mutation | 1 | 2008 | 2629 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1683 | 0.040 |
Why?
|
| Critical Care | 1 | 2022 | 402 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 5528 | 0.030 |
Why?
|
| Length of Stay | 2 | 2013 | 819 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 374 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 756 | 0.030 |
Why?
|
| Population Dynamics | 1 | 2017 | 20 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2013 | 5697 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 1561 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2003 | 2049 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 1176 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 2605 | 0.030 |
Why?
|
| Multiple Trauma | 1 | 2013 | 28 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2013 | 75 | 0.030 |
Why?
|
| Silk | 1 | 2011 | 7 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 4781 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 48 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2010 | 32 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 293 | 0.020 |
Why?
|
| Hernia | 1 | 2010 | 15 | 0.020 |
Why?
|
| Splenectomy | 1 | 2010 | 41 | 0.020 |
Why?
|
| Surgical Mesh | 1 | 2010 | 61 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 201 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 3318 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2013 | 870 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 215 | 0.020 |
Why?
|
| Peptides | 2 | 2002 | 590 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 412 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 104 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 859 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1385 | 0.020 |
Why?
|
| Nitrogen Isotopes | 1 | 2006 | 10 | 0.020 |
Why?
|
| Buffers | 1 | 2006 | 23 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 41 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 3726 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 1570 | 0.010 |
Why?
|
| Solutions | 1 | 2006 | 64 | 0.010 |
Why?
|
| Micelles | 1 | 2006 | 82 | 0.010 |
Why?
|
| Massachusetts | 1 | 2011 | 2096 | 0.010 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2006 | 272 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 495 | 0.010 |
Why?
|
| beta-Arrestin 2 | 1 | 2002 | 2 | 0.010 |
Why?
|
| beta-Arrestins | 1 | 2002 | 4 | 0.010 |
Why?
|
| Disintegrins | 1 | 2002 | 4 | 0.010 |
Why?
|
| Arrestins | 1 | 2002 | 6 | 0.010 |
Why?
|
| Peptides, Cyclic | 1 | 2002 | 24 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 2002 | 58 | 0.010 |
Why?
|
| Second Messenger Systems | 1 | 2002 | 27 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 98 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2009 | 1301 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2002 | 166 | 0.010 |
Why?
|
| Endocytosis | 1 | 2002 | 153 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 153 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2002 | 436 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 402 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 766 | 0.010 |
Why?
|